Natixis Advisors LLC Sells 1,163 Shares of IDEXX Laboratories, Inc. $IDXX

Natixis Advisors LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.5% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 46,245 shares of the company’s stock after selling 1,163 shares during the quarter. Natixis Advisors LLC owned about 0.06% of IDEXX Laboratories worth $29,545,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC raised its holdings in IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after acquiring an additional 15 shares during the period. STF Management LP lifted its position in IDEXX Laboratories by 1.3% during the second quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after acquiring an additional 16 shares during the last quarter. Clearstead Trust LLC boosted its holdings in shares of IDEXX Laboratories by 1.1% during the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after acquiring an additional 16 shares during the period. MassMutual Private Wealth & Trust FSB grew its position in shares of IDEXX Laboratories by 4.4% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock valued at $243,000 after purchasing an additional 16 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its position in shares of IDEXX Laboratories by 3.3% in the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after purchasing an additional 17 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the transaction, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock worth $29,862,109 in the last quarter. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Down 1.9%

NASDAQ IDXX opened at $598.85 on Wednesday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The company has a market cap of $47.68 billion, a price-to-earnings ratio of 45.82, a PEG ratio of 3.71 and a beta of 1.66. The company has a 50 day moving average of $663.72 and a 200-day moving average of $668.13. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IDXX. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Piper Sandler decreased their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. UBS Group lowered their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. BTIG Research dropped their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.